Skip to main content
SpringerLink
Log in

Drug-Nutrient Interactions Involving Folate

  • Chapter
Book cover Handbook of Drug-Nutrient Interactions

Part of the book series: Nutrition and Health ((NH))

Abstract

The importance of maintaining optimal folate status throughout all phases of the life cycle has grown increasingly apparent in recent years. Studies have produced convincing evidence linking folate deficiency to health risks that extend well beyond the classic association with macrocytic anemia. The strongest evidence exists for the relationship between folate deficiency and neural tube birth defects (1). Research also indicates that inadequate folate levels may increase risks for other types of birth defects, early miscarriage, atherosclerotic cardiovascular disease, some types of cancer, and neurological and neuropsychiatric disorders (2,3). Among the many factors that influence folate status, drug-nutrient interactions (DNIs) stand out as a significant, and largely avoidable, cause of folate deficiency (4).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 74.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Centers for Disease Control (CDC). Recommendations for the use of folic acid to reduce the number of cases of spinal bifida and other neural tube defects. MMWR, Recomm Rep 1992; 41 (RR14): 1–7.

    Google Scholar 

  2. Stanger O. Physiology of folic acid in health and disease. Curr Drug Metab 2002; 3: 211–223.

    Article  CAS  Google Scholar 

  3. National Institutes of Health (NIH). Facts about dietary supplements: Folate. Clinical Nutrition Service, Warren Grant Magnuson Clinical Center, Bethesda, MD, 2001. Available online: http://www.cc.nih.gov/ ccc/supplements/folate.pdf.

    Google Scholar 

  4. Haslam N, Probert CS. An audit of the investigation and treatment of folic acid deficiency. J R Soc Med 1998; 91: 72–73.

    CAS  Google Scholar 

  5. Herbert V. Folic acid. In: Shils ME, Olson JA, Shike M, et al., eds. Modern Nutrition in Health and Disease. Williams and Wilkens, Baltimore, 1999, pp. 433–446.

    Google Scholar 

  6. Bailey LB, Gregory JF.Folate metabolism and requirements. J Nutr 1999; 129: 779–782.

    CAS  Google Scholar 

  7. Clarke R, Collins MB, Lewington S, et al. Homocysteine and risk of ischemic heart disease and stroke. JAMA 2002; 288: 2015–2022.

    Article  CAS  Google Scholar 

  8. Mangoni AA, Jackson SH. Homocysteine and cardiovascular disease: current evidence and future prospects. Am J Med 2002; 112: 556–565.

    Article  CAS  Google Scholar 

  9. Institute of Medicine (IOM). Dietary reference intakes for thiamin, riboflavin, niacin, vitamin B6, folate, vitamin B12, pantothenic acid, biotin, and choline. National Academy Press, Washington DC, 1998, pp. 196–305.

    Google Scholar 

  10. Rader JI, Yetley EA. Nationwide folate fortification has complex ramifications and requires careful monitoring. Arch Intern Med 2002; 162: 608–609.

    Article  Google Scholar 

  11. Quinlivan EP, Gregory JF. Effect of food fortification on folic acid intake in the United States. Am J Clin Nutr 2003; 77: 221–225.

    CAS  Google Scholar 

  12. Bailey LB, Caudill MA.Folic acid. In: Baumgartner TG, ed. Clinical Guide to Parenteral Micronutrition Fujisawa, Deerfield, IL, 1997, pp. 611–628.

    Google Scholar 

  13. Suitor CW, Bailey LB. Dietary folate equivalents: interpretation and application. J Am Diet Assoc 2000; 100: 88–94.

    Article  CAS  Google Scholar 

  14. Butterworth CE, Tamura T. Folic acid safety and toxicity: a brief review. Am J Clin Nutr 1989; 50: 353–358.

    CAS  Google Scholar 

  15. Shane B. Folate fortification: Enough is enough? Am J Clin Nutr 2003; 77: 8–9.

    CAS  Google Scholar 

  16. Smulders YM, deMan AM, Stehouwer CD, et al. Trimethoprim and fasting plasma homocysteine. Lancet 1998; 352: 1827–1828. [Erratum, Lancet 1999;353:758.]

    Google Scholar 

  17. Varela-Moreiras G.Nutritional regulation of homocysteine: effects of drugs. Biomed Pharmacother 2001;55:448–453.

    Google Scholar 

  18. Calvert H. Folate status and the safety profile of antifolates. Semin Oncol 2002; 29 (2 Suppl 5): 3–7.

    Article  CAS  Google Scholar 

  19. Hernandez-Diaz S, Werler MM, Walker AM, Mitchell AA. Folic acid antagonists and the risk of birth defects. N Engl J Med 2000; 343: 1608–1614.

    Article  CAS  Google Scholar 

  20. Lambie DG, Johnson RH. Drugs and folate metabolism. Drugs 1985; 30: 145–155.

    Article  CAS  Google Scholar 

  21. Calvert H. An overview of folate metabolism: Features relevant to the action and toxicities of antifolate anticancer agents. Semin Oncol 1999; 26 (2 Suppl 6): 3–10.

    CAS  Google Scholar 

  22. Malinow MR, Duell PB, Williams MA, et al. Short-term folic acid supplementation induces variable and paradoxical changes in plasma homocysteine concentrations. Lipids 2001; S27–S32.

    Google Scholar 

  23. Lewis DP, VanDyke DC, Willhite LA, Stumbo PJ, Berg MJ. Phenytion-folic acid interaction. Ann Pharmacother 1995; 29: 726–735.

    CAS  Google Scholar 

  24. Seligmann H, Potasman I, Weller B, Schwartz M, Prokocimer M. Phenytoin-folic acid interaction: A lesson to be learned. Clin Neuropharmacol 1999; 22 (5): 268–272.

    CAS  Google Scholar 

  25. Ortiz Z, Shea B, Suarez-Almazor ME, Moher D, Wells GA, Tugwell P. The efficacy of folic acid and folinic acid in reducing methotrexate gastrointestinal toxicity in rheumatoid arthritis. A metaanalysis of randomized controlled trials. J Rheumatol 1998; 25: 36–43.

    CAS  Google Scholar 

  26. VanEde AE, Laan RF, Rood JM., Huizinger TW, van de Laar MA, van Deren CJ. Effect of folinic acid supplelmentation on the toxicity and efficacy of methotrexate in rheumatoid arthritis. Arthritis Rheum 2001; 44: 1515–1524.

    Article  CAS  Google Scholar 

  27. American Academy of Neurology: Practice parameter: Management issues for women with epilepsy. Report of the Quality Standard Subcommittee of the American Academy of Neurology. Neurology 1998; 51: 944–948.

    Article  Google Scholar 

  28. American College of Obstetric and Gynecologic Physicians: Education Bulletin. Seizure disorders in pregnancy 1996; 231: 1–13.

    Google Scholar 

  29. Eller DP, Patterson CA,Webb GW. Prescribing in pregnancy: maternal and fetal implications of anti-convulsive therapy during pregnancy. Obstet Gynecol Clin North Am 1997; 24: 523–534.

    Article  CAS  Google Scholar 

  30. Nulman I, Laslo D, Koren, G. Treatment of epilepsy in pregnancy. Drugs 1999; 57: 535–544.

    Article  CAS  Google Scholar 

  31. Lewis DP, Van Dyke DC, Stumbo PJ, Berg MJ. Drug and environmental factors associated with adverse pregnancy outcomes part III: Folic acid: Pharmacology, therapeutic recommendations, and economics. Ann Pharmacother 1998; 32: 1087–1095.

    Article  CAS  Google Scholar 

  32. Morrell MJ. Folic acid and epilepsy. Epilepsy Currents 2001; 2: 31–34.

    Article  Google Scholar 

  33. McAuley JW, Anderson GD. Treatment of epilepsy in women of reproductive age: pharmacokinetic considerations. Clin Pharmacokinet 2002; 41: 559–579.

    Article  CAS  Google Scholar 

  34. Morrell MJ.Guidelines for the care of women with epilepsy. Management of Epilepsy: Consensus conference on current clinical practice. Neurology 1998; 51: S21–S27.

    Google Scholar 

  35. Kishi T, Fujita N, Eguchi T, Ueda K. Mechanism for reduction of serum folate by antiepileptic drugs during prolonged therapy. J Neurol Sci 1997; 145: 109–112.

    Article  CAS  Google Scholar 

  36. Leucovorin Product Information: Irvine, CA. Gensia Sicor Pharmaceuticals, June 1998.

    Google Scholar 

  37. Slot O.Changes in plasma Homocysteine in arthritis patients starting treatment with low-dose methotrexate subsequently supplemented with folic acid. Scand J Rheumatol 2001; 30: 305–307.

    Google Scholar 

  38. Morgan SL, Baggott JE, Lee JY, Alarcon GS. Folic acid supplementation prevents deficient folate levels and hyperhomocysteinemia during long-term, low dose methotrexate therapy for rheumatoid arthritis: Implications for cardiovascular disease prevention. J Rheumatol 1998; 25: 441–446.

    CAS  Google Scholar 

  39. VanEde AE, Laan RF, Blom, HJ, Boers GH, Haagsma CJ, Thomas CM. Homocysteine and folate status in methotrexate-treated patients with rheumatoid arthritis. Rheumatology 2002; 41: 658–665.

    Article  CAS  Google Scholar 

  40. Ortiz Z, Shea B, Suarez-Alamazor ME, et al. Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis. (Cochrane Review). In The Cochrane Library, Issue 4, Update Software, Oxford, 2002.

    Google Scholar 

  41. Morgan SL, Baggott JE, Vaughn WH, et al. Supplementation with folic acid during methotrexate therapy for rheumatoid arthritis: A double-blind, placebo controlled trial. Ann Int Med 1994; 121: 833–841.

    Article  CAS  Google Scholar 

  42. American College of Rheumatology Ad Hoc Committee on Clinical Guidelines.Guidelines for monitoring drug therapy in rheumatoid arthritis. Arthritis Rheum 1996; 39: 723–731.

    Article  Google Scholar 

  43. Alarcon GS, Morgan, SL. Guidelines for monitoring drug therapy in rheumatoid arthritis: comment on the guidelines for monitoring drug therapy. Arthritis Rheum 1997; 40: 391–392.

    Article  CAS  Google Scholar 

  44. Shiroky JB. The use of folates concomitantly with low-dose pulse methotrexate. Rheum Dis Clin North Am 1997; 23: 969–980.

    Article  CAS  Google Scholar 

  45. Joyce, DA, Will, RK, Hoffman, DM, Laing B, Blackbourn SJ. Exacerbation of rheumatoid arthritis in patients treated with methotrexate after administration of folinic acid. Ann Rheum Dis 1991; 50: 913–914.

    Article  CAS  Google Scholar 

  46. Machover D, Schwarzenberg L, Goldschmidt E, et al. Treatment of advanced colorectal and gastric adenocarcinoma with 5-FU combined with high dose folinic acid: a pilot study. Cancer Treat Rep 1982; 66: 1803–1807.

    CAS  Google Scholar 

  47. Stein TA, Burns GP, Bailey B, Citron ML. l. 5-fluorouracil pharmacokinetics in patients with metastatic colorectal carcinoma after high-dose leucovorin. Cancer Invest 1994; 12: 375–378.

    Article  CAS  Google Scholar 

  48. Richards FO, Kovacs JA, Luft BJ. Preventing toxoplasmic encephalitis in persons infected with human immunodeficiency virus. Clin Infect Dis 1995; 21: S49–S56.

    Article  Google Scholar 

  49. Helmer RE. Hazards of folinic acid with pyrimethamine and sulfadiazine. Ann Int Med 1975; 82: 124–125.

    Google Scholar 

  50. Van Delden C, Hirschel B. Folinic acid supplements to pyrimethamine-sulfadiazine for Toxoplasma encephalitis are associated with better outcomes. J Infect Dis 1996; 173: 1294–1295.

    Article  Google Scholar 

  51. Tong MJ, Strickland GT, Votteri BA, Gunning JJ. Supplemental folates in the therapy of plasmodium falciparum malaria. JAMA 1970; 214: 2330–2333.

    Article  CAS  Google Scholar 

  52. Safrin S, Lee BL, Sande MA. Adjunctive folinic acid with trimethoprim-sulfamethoxazole for Pneumocystis carinii pneumonia in AIDS patients is associated with an increased risk of therapeutic failure and death. J Infect Dis 1994; 170: 912–917.

    Article  CAS  Google Scholar 

  53. Coppen A, Swade C, Jones SA, Armstrong RA, Blair JA, Leeming RJ. Depression and tetrahydrobiopterin: the folate connection. J Affect Disord 1989; 16: 103–107.

    Article  CAS  Google Scholar 

  54. Coppen A, Chaudhry S, Swade C. Folic acid enhances lithium prophylaxis. J Affect Disord 1986; 10: 9–13.

    Article  CAS  Google Scholar 

  55. Coppen A, Baily J. Enhancement of the antidepressant action of fluoxetine by folic acid: a randomised, placebo controlled trial. J Affect Disord 2000; 60: 121–130.

    Article  CAS  Google Scholar 

  56. Morrow LE, Grimsely EW. Long-term diuretic therapy in hypertensive patients: effects on serum homocysteine, vitamin B6, vitamin B12, and red blood cell folate concentrations. Southern Medical J 1999; 92: 866–870.

    Article  CAS  Google Scholar 

  57. Sidholm MB, Velez MR. Monitoring the effect of triamterene and hydrochlorothiazide on dehydrofolate reductase activity using a new spectrophotometric method. J Pharm Biomed Anal 1989; 7: 1551–1557.

    Article  Google Scholar 

  58. Russell DM, Dutta SK, Rosenberg IH, Giovetti AC. Impairment of folic acid by oral pancreatic extracts. Dig Dis Sci 1980; 25: 369–373.

    Article  CAS  Google Scholar 

  59. Krogh JM, Ekelund S, Svendsen L. Folate and homocysteine status and haemolysis in patients treated with sulphasalazine for arthritis. Scand J Clin Lab Invest 1996; 56: 421–429.

    Article  Google Scholar 

  60. Graham TO, Kandil HM. Nutritional factors in inflammatory bowel disease. Gastroenterol Clin N Am 2002; 31: 203–218.

    Article  Google Scholar 

  61. Smith CL, Powell KR. Review of sulfonamides and trimethoprim. Pediatr Rev 2000; 21: 368–371.

    CAS  Google Scholar 

  62. Kane S. Inflammatory bowel disease in pregnancy. Gastroenterol Clin N Am 2003; 32: 323–340.

    Article  Google Scholar 

  63. Pironi L. Cornia GL. Ursitti MA, et al. Evaluation of oral administration of folic and folinic acid to prevent folate deficiency in patients with inflammatory bowel disease treated with salicylazosulfapyridine. Int J Clin Pharmacol Res 1988; 8: 143–148.

    CAS  Google Scholar 

  64. Logan EC, Williamson LM, Ryrie DR. Sulphasalazine associated pancytopenia may be caused by acute folate deficiency. Gut 1986; 27: 868–872.

    Article  CAS  Google Scholar 

  65. Leonard JP, Desager JP, Beckers C, Harvengt C. In vitro binding of various biological substances by two hypocholesterolaemic resins. Arzneimittelforschung 1979; 29: 979–981.

    CAS  Google Scholar 

  66. West RJ, Lloyd JK. The effect of cholestyramine on intestinal absorption. Gut 1975; 16: 93–98.

    Article  CAS  Google Scholar 

  67. Questran. Product Information. Bristol Myers Squibb, Princeton, NJ, March 1999.

    Google Scholar 

Download references

Authors
  1. Leslie Schechter
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Patricia Worthington
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Pharmacy Practice, Temple University School of Pharmacy, Philadelphia, PA, USA

    Joseph I. Boullata PharmD, BCNSP

  2. Department of Surgery, Temple University School of Medicine, Philadelphia, PA, USA

    Vincent T. Armenti MD, PhD

Rights and permissions

Reprints and permissions

Copyright information

© 2004 Springer Science+Business Media New York

About this chapter

Cite this chapter

Schechter, L., Worthington, P. (2004). Drug-Nutrient Interactions Involving Folate. In: Boullata, J.I., Armenti, V.T. (eds) Handbook of Drug-Nutrient Interactions. Nutrition and Health. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-781-9_15

Download citation

  • DOI: https://doi.org/10.1007/978-1-59259-781-9_15

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-4757-5359-2

  • Online ISBN: 978-1-59259-781-9

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation